Short- and Mid-Term Intravascular Ultrasound Analysis of the New Zotarolimus-Eluting Stent With Durable Polymer
Authors:
- 1 January 2010
- journal article
- clinical trial
- Published by Japanese Circulation Society in Circulation Journal
- Vol. 74 (10) , 2097-2102
Abstract
The Resolute stent is a newly developed system with a bio-histocompatible polymer that allows programmed drug delivery up to 180 days. The aim of this intravascular ultrasound (IVUS) analysis was to evaluate the short- (4 months) and mid-term (9 months) efficacy using the Resolute stent. Data were derived from the RESOLUTE trial, a prospective, multicenter, non-randomized, single-arm study to treat de novo native coronary artery lesions. This trial included 2 cohorts with different follow-up periods, and all enrollment patients in this trial received IVUS study. Follow-up IVUS was available in 24 patients (4-month group) and 88 patients (9-month group). Neointimal obstruction (%) was defined as neointimal volume divided by stent volume. Cross-sectional narrowing (CSN, %) was defined as neointimal area divided by stent area. No significant differences in vessel, lumen and stent volume at post-procedure were observed within stented segments between the 4- and 9-month follow-up groups. Although neointimal volume and % neointimal obstruction showed no significant difference between the 2 groups (% neointimal obstruction: 2.2 ± 2.5 vs 3.7 ± 4.0%, P=0.09), maximum CSN was significantly larger in the 9-month group. There were 7 cases of late incomplete stent apposition. These IVUS results showed minimum growth of neointimal proliferation by the Resolute stent throughout the stented segment up to 9 months follow up.Keywords
This publication has 30 references indexed in Scilit:
- Clinical and Angiographic Results With the Next-Generation Resolute Stent SystemJACC: Cardiovascular Interventions, 2009
- Drug-Eluting Stents Insights From Invasive Imaging TechnologiesCirculation Journal, 2009
- Analysis of left main coronary artery bifurcation lesions treated with biolimus‐eluting DEVAX AXXESS plus nitinol self‐expanding stent: Intravascular ultrasound results of the AXXENT trialCatheterization and Cardiovascular Interventions, 2008
- Novel drug eluting stent system for customised treatment of coronary lesions: CUSTOM I feasibility trial 24 month resultsEuroIntervention, 2008
- Comparison of an Everolimus-Eluting Stent and a Paclitaxel-Eluting Stent in Patients With Coronary Artery DiseaseJAMA, 2008
- Comparison of vascular response to zotarolimus-eluting stent versus sirolimus-eluting stent: Intravascular ultrasound results from ENDEAVOR IIIAmerican Heart Journal, 2008
- Detailed Intravascular Ultrasound Analysis of Zotarolimus-Eluting Phosphorylcholine-Coated Cobalt-Chromium Alloy Stent in de Novo Coronary Lesions (Results from the ENDEAVOR II Trial)††Conflicts of interest: Dr. Fitzgerald has worked as a consultant for Medtronic Vascular. Dr. Kuntz is currently an employee of Medtronic Vascular.The American Journal of Cardiology, 2007
- Sirolimus-Eluting Stents versus Standard Stents in Patients with Stenosis in a Native Coronary ArteryNew England Journal of Medicine, 2003
- Two-Year Angiographic and Intravascular Ultrasound Follow-Up After Implantation of Sirolimus-Eluting Stents in Human Coronary ArteriesCirculation, 2003
- 7-Hexanoyltaxol–Eluting Stent for Prevention of Neointimal GrowthCirculation, 2002